Speaker:

Russell I. Heigh, MD  Associate Professor of Medicine, Mayo Clinic College of Medicine; Consultant, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona; Associate Medical Director, Provider Relations, Affiliated Practice Network, Mayo Clinic Care Network, Mayo Clinic, Scottsdale, Arizona. Chair, Arizona Government Relations Core Team, Executive Operations Team, Mayo Clinic, Arizona. 

Virginia A. Warren  Office Chief, Cancer Prevention and Control Programs; Well Woman HealthCheck Program, Colorectal Cancer and Comprehensive Cancer Control, Arizona Department of Health Services.

Objectives: 

• Review and analyze the latest 2016 guidelines of the USPSTF
• Consider the issues associated with adding the new FIT-DNA stool test to your toolkit
• Explore ASA chemoprevention of colorectal neoplasia as recommended in 2016 by the USPSTF
• Recognize that cancer is the leading cause of death in Arizona and that colorectal cancer is commonly diagnosed at late stage
• Cite that Arizona has had two Colorectal Cancer Roundtables and now has a permanent Colorectal Cancer Task Force
• Identify how to contact the Arizona Cancer Coalition and be involved in the work of the Coalition

MMI Presentation:

Thomas DeLeon, M.D.

Locations:    

• Mayo Clinic Building, Taylor Auditorium
• Mayo Clinic Hospital, MCH Waugh Auditorium Side A (MCH 1-220A)
• Mayo Clinic Women’s Health Internal Medicine
• Mayo Clinic Family Medicine – Arrowhead
• Kingman Regional Medical Center
• Yuma Regional Medical Center
• Canyon Ranch Medical Center
• Mayo Clinic Primary Care – San Tan

ALL PHYSICIANS AND ALLIED STAFF ARE WELCOME

**NEW** ATTENDANCE REQUIREMENT 
A unique presentation code must be sent via text to 507-200-3010 
to record attendance and to ensure you receive CME credit for your attendance.  
NOTE:  Attendees must be present to receive code.  

FACULTY DISCLOSURE

As a provider accredited by Accreditation Council on Continuing Medical Education (ACCME), Mayo Clinic College of Medicine, must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships is included course materials so participants may formulate their own judgments regarding the presentation.